| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,960,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile 9 Meters Biopharma is a clinical-stage company. Co.'s product development pipeline include: Vurolenatide, which is a long-acting glucagon-like peptide-1 receptor agonist that combines exenatide with a proprietary extended half-life technology for treatment of short bowel syndrome; Larazotide, which is being developed for the treatment of celiac disease; NM-102, which is a small molecule peptide that is being developed as a potential microbiome modulator and is undergoing an indication selection process; and NM-003, which is a proprietary long-acting glucagon-like peptide-2 agonist with improved serum half-life compared with short-acting versions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
472,383 |
| Total Buy Value |
$0 |
$0 |
$0 |
$151,319 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
9,100 |
| Total Sell Value |
$0 |
$0 |
$0 |
$11,011 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sirgo Mark A |
Director |
– • – |
2020-04-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,441 |
|
-12% |
|
| Temperato John |
Chief Executive OfficerOfficer |
• • – |
2020-04-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,441 |
|
-12% |
|
| Darvish Nissim |
Director |
– • • |
2020-04-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
16,986,521 |
|
-12% |
|
| Orbimed Israel Biofund Gp Limited Partnership |
Director |
– • • |
2020-04-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
16,986,521 |
|
-12% |
|
| Laumas Sandeep |
CEO, Executive Chairman |
• • – |
2019-06-28 |
4 |
B |
$1.15 |
$4,600 |
D/D |
4,000 |
18,000 |
2.73 |
- |
|
| Laumas Sandeep |
CEO, Executive Chairman |
• • – |
2019-06-13 |
4 |
B |
$1.21 |
$1,216 |
D/D |
1,000 |
14,000 |
2.73 |
- |
|
| Madan Jay P. |
President |
• • – |
2019-05-30 |
4 |
B |
$1.32 |
$6,600 |
D/D |
5,000 |
84,131 |
2.81 |
- |
|
| Proujansky Roy |
Director |
– • – |
2019-05-24 |
4 |
B |
$1.28 |
$1,280 |
D/D |
1,000 |
2,400 |
2.31 |
- |
|
| Laumas Sandeep |
CEO, Executive Chairman |
• • – |
2019-05-22 |
4 |
B |
$1.38 |
$6,900 |
D/D |
5,000 |
13,000 |
2.81 |
- |
|
| Proujansky Roy |
Director |
– • – |
2018-11-30 |
4 |
B |
$2.63 |
$3,682 |
D/D |
1,400 |
1,400 |
2.31 |
- |
|
| Laumas Sandeep |
Executive Chairman |
• • – |
2018-11-30 |
4 |
B |
$2.62 |
$7,890 |
D/D |
3,000 |
8,000 |
2.81 |
- |
|
| Prior Christopher P. |
Chief Executive Officer |
• • – |
2018-11-29 |
4 |
B |
$2.75 |
$13,750 |
D/D |
5,000 |
7,009 |
2.81 |
- |
|
| Laumas Sandeep |
Executive Chairman |
• • – |
2018-11-29 |
4 |
B |
$2.55 |
$7,670 |
D/D |
3,000 |
5,000 |
2.81 |
- |
|
| Prior Christopher P. |
Chief Executive Officer |
• • – |
2018-09-14 |
4 |
B |
$5.82 |
$1,164 |
D/D |
200 |
2,009 |
2.73 |
- |
|
| Prior Christopher P. |
Chief Executive Officer |
• • – |
2018-09-12 |
4 |
B |
$6.13 |
$3,065 |
D/D |
500 |
1,809 |
2.73 |
- |
|
| Laumas Sandeep |
Executive Chairman |
• • – |
2018-09-07 |
4 |
B |
$6.10 |
$3,050 |
D/D |
500 |
2,000 |
2.73 |
- |
|
| Laumas Sandeep |
Executive Chairman |
• • – |
2018-08-30 |
4 |
B |
$5.24 |
$2,620 |
D/D |
500 |
750 |
2.73 |
- |
|
| Prior Christopher P. |
Chief Executive Officer |
• • – |
2018-08-30 |
4 |
B |
$5.20 |
$1,607 |
D/D |
309 |
1,309 |
2.73 |
- |
|
| Laumas Sandeep |
Executive Chairman |
• • – |
2018-08-28 |
4/A |
B |
$4.90 |
$1,225 |
D/D |
250 |
250 |
2.73 |
- |
|
| Prior Christopher P. |
Chief Executive Officer |
• • – |
2018-08-28 |
4 |
B |
$4.93 |
$4,930 |
D/D |
1,000 |
1,000 |
2.73 |
- |
|
| Laumas Sandeep |
Executive Chairman |
• • – |
2018-08-28 |
4 |
B |
$4.88 |
$3,759 |
D/D |
750 |
1,000 |
2.73 |
- |
|
| Almenoff June Sherie |
COO and Chief Medical Officer |
• – – |
2018-08-27 |
4 |
B |
$4.90 |
$1,979 |
I/I |
400 |
900 |
1.91 |
- |
|
| Almenoff June Sherie |
COO and Chief Medical Officer |
• – – |
2018-08-24 |
4 |
B |
$4.85 |
$4,906 |
I/I |
1,000 |
1,400 |
1.91 |
- |
|
| Clarke David H |
Former CEO and Director |
• • – |
2018-01-26 |
4 |
B |
$0.35 |
$105,000 |
I/I |
300,000 |
1,718,450 |
2.66 |
- |
|
| Olert David Lewis |
Former CFO |
• – – |
2018-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
70,000 |
|
- |
|
110 Records found
|
|
Page 3 of 5 |
|
|
